Asthma affects more than 25 million Americans and ranges from mild, occasional symptoms to severe disease requiring daily controller medications. Current treatment centers on inhaled corticosteroids and bronchodilators, but about 10% of people have severe asthma that doesn't respond well to standard inhalers. Biologics targeting specific inflammatory pathways have opened new options for people whose asthma remains uncontrolled.
What's actually going on in research
Trials are testing new biologics that target different parts of the immune system, long-acting bronchodilators combined with anti-inflammatory drugs, and treatments for specific asthma types identified by biomarkers. Researchers are also studying whether early aggressive treatment in children can change the disease course, and testing drugs that may reduce the airway remodeling that happens over time.
Targeted biologics
Drugs like dupilumab, mepolizumab, and benralizumab block specific immune signals that drive severe asthma. Trials are testing new biologics targeting different pathways and studying which patients benefit most from which drug.
Bronchial thermoplasty
This procedure uses heat to reduce excess smooth muscle in airways. Studies are refining who benefits and developing improved devices.
Pediatric prevention
Trials in young children are testing whether starting controller medications early, even before asthma is diagnosed, can prevent airway damage. Some studies focus on children at high risk based on wheezing patterns and allergies.
What to know before you search
Eligibility typically depends on asthma severity, how often symptoms occur, lung function tests, biomarker levels like eosinophil count or IgE, and what medications you're currently taking.
What types of trials are currently open
- Biologic trials — Testing new injectable or infused drugs that target specific immune pathways. These trials typically enroll people with severe asthma not controlled by standard inhalers.
- Inhaler trials — Testing new combinations of inhaled medications, often comparing once-daily or single-inhaler options to current multi-inhaler regimens.
- Pediatric trials — Studies in children testing early treatment approaches, new formulations designed for young children, and whether aggressive early control changes long-term outcomes.
- Severe asthma trials — Testing treatments for people who have frequent attacks despite maximum standard therapy. May include biologics, add-on pills, or procedures.
- Phenotype studies — Research identifying different asthma types based on biomarkers, aiming to match treatments to specific disease mechanisms.
Recently added Asthma trials
Share your asthma or COPD treatment data over 12 months
This prospective, real-world observational study (T2AIR Study) evaluates the long-term efficacy and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and depemokimab - in patients with chronic airway diseases, including asthma and COPD under routine clinical practice in China. The primary objective is to determine the annualized exacerbation rate (AER) over 12 months of treatment. Secondary objectives include time to first exacerbation, frequency of severe exacerbations, improvements in symptom control and quality of life (using disease-specific questionnaires), lung function (FEV₁, FVC), airway inflammatory biomarkers (FeNO, blood eosinophils, serum IgE), oral corticosteroid (OCS) sparing effect in asthma patients, and treatment persistence. Safety outcomes will assess the incidence, types, and severity of adverse events (AEs) and serious adverse events (SAEs). Exploratory endpoints include high-resolution CT (HRCT)-based imaging markers of airway remodeling and the development of deep learning-based multimodal predictive models integrating clinical, biomarker, and radiomics data to support personalized treatment. Additionally, blood, sputum, and urine samples will be collected for translational research to explore underlying mechanisms and predictors of biologic response. This study aims to generate robust real-world evidence on the effectiveness and safety of Type 2-targeted biologics across the broad spectrum of chronic airway diseases in a diverse Chinese patient population.
Try a program connecting your medical, school, and home care for asthma
This study pilots REACH, Resources and Education for Addressing Chronic Health, a service model to facilitate care coordination and communication across medical, school, and home settings. REACH seeks to address barriers to school-based asthma management, improving health and educational outcomes and reducing negative impacts for children with asthma.
Find Asthma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.